Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece

Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece: The ADMIRE Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05683912

Acronym

ADMIRE

Enrollment

100

Registered

2023-01-13

Start date

2019-09-01

Completion date

2022-12-15

Last updated

2023-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema

Brief summary

ADMIRE was a prospective, observational cohort study of patients with diabetic macular edema (DME). Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to months 12, 24 and 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.

Interventions

DRUGAflibercept

Intravitreal aflibercept as used in the routice clinical practice

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

45 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with DM, able to give written informed consent Patients with DME\>320 μm, who need treatment

Exclusion criteria

Patients with other retinal diseases than DME Intraocular surgery within the last 6 months

Design outcomes

Primary

Measure	Time frame
Change in best-corrected visual acuity	12 months

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026